UK Markets close in 6 hrs 3 mins

Achiko AG invites shareholders to its Annual General Meeting on 26 May 2021

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
  • Oops!
    Something went wrong.
    Please try again later.

Achiko AG / Key word(s): AGMEGM

27-Apr-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

Achiko AG invites shareholders to its Annual General Meeting on 26 May 2021

- Annual General Meeting of shareholders to be held on 26 May 2021

- Due to the Covid-19 pandemic, the meeting will be held without physical presence of the shareholders

- John Bing-Tsung Lin to retire from the Board of Directors at the Annual General Meeting and Dr Jittaporn Wattanaseree will depart from the Advisory Board with the publication of the Annual Report 2020


Zurich, 27 April 2021 - Achiko AG (SWX: ACHI, ISIN CH0522213468) has published the notice regarding the Annual General Meeting at 10:00 a.m. (CEST) on 26 May 2021 in Zurich.

Due to the Covid-19 pandemic, this year's Annual General Meeting will be held in accordance with art. 27 para. 1 letter b Covid-19-Ordinance 3 without physical presence of the shareholders. Shareholders may exercise their shareholders' rights through the independent proxy only, as further set out in the invitation to the Annual General Meeting. The Board of Directors regrets not being able to welcome the shareholders to the Annual General Meeting this year and requests shareholders to make use of the participation option through the independent proxy.

Only shareholders that are registered with their personal information in the Company's shareholder ledger may participate in the Annual General Meeting. Unregistered shareholders who wish to participate in the Annual General Meeting are kindly requested to contact the financial institution that holds the respective shares and request their registration. The cut-off date for the participation in the Annual General Meeting is 10 May 2021. Only shareholders entered in the shareholder ledger with the right to vote until May 10, 2021 will be entitled to participate in the Annual General Meeting. For technical and legal reasons, shares cannot be registered directly through Achiko AG.

In addition to the standard agenda items of the Annual General Meeting, the Company announces the retirement of Board member John Bing-Tsung Lin from the Board of Directors as of the Company's 2021 Annual General Meeting. Mr Lin has served on the Board since 2018 and his leadership and collaboration on the Board will be greatly missed. After a valuable contribution over a short period of time, Dr Jittaporn Wattanaseree departs from the Advisory Board as of the publication of the Annual Report 2020 on 28 April 2021.

The Board of Directors is grateful for the contributions of Mr Lin and Dr Jittaporn Wattanaseree and would like to thank them for their efforts.

The invitation to the Annual General Meeting of Achiko AG with the full agenda and proposals of the Board of Directors plus further information will be published on 28 April 2021. The Annual Report 2020 with the annual result as of 31 December 2020 will also be published on 28 April 2021. Both the invitation and Annual Report will be available at https://www.achiko.com/financials.

About Achiko AG
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX, and its sister digital mobile health technology division, Teman Sehat. The Company has created a unique telehealth capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the management of Covid-19.

AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialisation rights.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.

Further information can be found at www.achiko.com.

If you have any questions regarding the Company, please contact us.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

Germany and Austria
Axel Mühlhaus / Dr Sönke Knop
edicto GmbH
E: achiko@edicto.de
T: +49 69 90 55 05-51

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


End of ad hoc announcement

Language:

English

Company:

Achiko AG

Tessinerplatz 7

8002 Zurich

Switzerland

E-mail:

ir@achiko.com

Internet:

https://www.achiko.com/

ISIN:

CH0522213468

Valor:

48788430

Listed:

SIX Swiss Exchange

EQS News ID:

1188407


 

End of Announcement

EQS Group News Service

show this
show this